SubHero Banner

Lynparza® (olaparib) – New indication

January 12, 2018 - The FDA announced the approval of AstraZeneca’s Lynparza (olaparib) tablets, for patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer, who have previously been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting.

Download PDF